Radiopharm Theranostics announces the appointment of new CEO

Latest News

Radiopharm Theranostics has announced the appointment of Riccardo Canevari as its new chief executive officer.

The company is developing a platform of radiopharmaceutical and nuclear medicine products for both diagnostic and therapeutic uses.

Mr Canevari joins Radioharm Theranostics from Novartis, where he held a range of senior positions over the past 20 years. He most recently served as the chief commercial officer of Advanced Accelerator Applications, the radiopharmaceutical company within Novartis, where he led Global Commercial Strategy in 20 markets across North America, Europe and Asia.

He previously served as senior vice president and global head of Novartis Oncology’s breast cancer franchise.

Mr Canevari, who is based in New York, has also held general manager and country resident positions for Novartis in Greece and in the South-Eastern European Cluster.

Radiopharm Theranostics has assembled a team of industry experts including Mr Canevari to lead the development of its portfolio. Professor David Mozley, the former Professor of Nuclear Medicine at Cornell University, recently joined as chief medical officer while Dr Thom Tulip was appointed chief technical officer.

According to Radiopharm Theranostics Executive Chairman Paul Hopper, “We are thrilled to welcome someone of this calibre from the radiopharmaceutical space to Radiopharm, who will help take the company to the next stage of its development with a highly promising portfolio of assets.

"Mr Canevari has spent more than two decades in the industry and has been very successful at a leading worldwide player in Novartis, experience that will be invaluable here.

"With our leadership team now settled after the recent appointments of Prof. David Mozley and Dr Thom Tulip, we are excited to work toward development of our technology and building out the Radiopharm Theranostics business.”

This new leadership announcement follows the recent announcement that the company raised $20 million via convertible notes to progress its radiopharmaceutical assets for diagnostic and therapeutic applications. 

Radiopharmaceuticals are radioactive drugs that can either act as a diagnostic, allowing physicians to see and to measure disease within the body, or as a therapeutic where high energy particles are emitted to treat malignant tumours, cancer and other diseases.